Search - tctmd.com

Displaying 841 - 860 of 2992

Sort: Relevancy | Date

Presentation TCT 2019

TCT 44: Impact of Stent Edge Hinging on Chronic Neointimal Hyperplasia after Newer Generation Drug-Eluting Stent Placement in RCA

Presenter: Takahiro Jimba

September 25, 2019

Presentation TCT 2019

TCT 11: Everolimus-eluting Bioresorbable Scaffolds versus Drug-eluting Stents in Patients with Acute Myocardial Infarction – 2-Year Results of the Randomized ISAR-Absorb MI Trial

Presenter: Jens Wiebe

September 25, 2019

Presentation TCT 2019

TCT 43: A Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Stent in the Treatment of Subjects with up to two de novo Coronary Artery Lesions – BIOFLOW IV: 4 Years Clinical Results

Presenter: Bernhard Witzenbichler

September 25, 2019

Presentation TCT 2019

TCT 42: Polymer-free Drug-coated vs. Bare-metal Coronary Stents in Patients Undergoing Non-cardiac Surgery A Subgroup Analysis of the LEADERS FREE Trial

Presenter: Abdelhakim Allali

September 25, 2019

Presentation TCT 2019

Industry Perspective on Drug-Eluting Technologies Guidance

Presenter: Mark Pacyna

September 25, 2019

Presentation TCT 2019

TCT 41: A prospective multicentre randomized all-comers trial to assess the safety and effectiveness of the ultra-thin-strut sirolimus-eluting coronary stent Supraflex: 2-year results of the TALENT trial

Presenter: Azfar Zaman

September 25, 2019

Presentation TCT 2019

FDA Perspective and Revised Guidance

Presenter: Eleni Whatley

September 25, 2019

Presentation TCT 2019

New Data Regarding Drug-Eluting Technologies

Presenter: Krishna Rocha-Singh

September 25, 2019

Presentation TCT 2019

An Unforeseen Setback: Summary Level Meta-Analysis Brings Practice Back to the 1990s.

Presenter: Michael Jaff

September 25, 2019

Presentation TCT 2019

Case Example: Contemporary DES Thrombosis

Presenter: Amir Darki

September 25, 2019

Presentation TCT 2019

Drug-Eluting Stent Thrombosis and Restenosis: Mechanisms, Frequency, and Treatment

Presenter: Binita Shah

September 25, 2019

Presentation TCT 2019

Case Example: Complex DES With Long-Term Outcomes

Presenter: Anita Paggi

September 25, 2019

Presentation TCT 2019

Drug-Eluting Stent Platforms and Outcomes 2019

Presenter: Roberto Diletti

September 25, 2019

Presentation TCT 2019

Drug-Coated Balloons: State of the Art in the Face of Controversy

Presenter: Antonio Colombo

September 25, 2019

News Conference News TCT 2019

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

Shelley Wood

September 19, 2019

News Opinion Editor's Corner TCT 2018

My Takeaways From TCT 2018: Sunglasses, Shadows, and the COAPT Eclipse

Shelley Wood

October 12, 2018

News Opinion Off Script TCT 2018

Off Script: Phantom Hearts and the Elusive Nature of Angina

Kwan S. Lee

October 11, 2018

News Conference News TCT 2018

Human vs Machine: Computer Algorithm Matches Experts for PCI Appropriateness and Planning

Yael L. Maxwell

October 11, 2018

News Conference News TCT 2018

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

Michael O'Riordan

October 02, 2018

News Conference News TCT 2018

‘Enabling Strategies’ Improve Success of Chronic Total Occlusion PCI

TCT Daily Staff

September 28, 2018

Advertisement

TCT 44: Impact of Stent Edge Hinging on Chronic Neointimal Hyperplasia after Newer Generation Drug-Eluting Stent Placement in RCA

TCT 11: Everolimus-eluting Bioresorbable Scaffolds versus Drug-eluting Stents in Patients with Acute Myocardial Infarction – 2-Year Results of the Randomized ISAR-Absorb MI Trial

TCT 43: A Prospective Randomized Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Stent in the Treatment of Subjects with up to two de novo Coronary Artery Lesions – BIOFLOW IV: 4 Years Clinical Results

TCT 42: Polymer-free Drug-coated vs. Bare-metal Coronary Stents in Patients Undergoing Non-cardiac Surgery A Subgroup Analysis of the LEADERS FREE Trial

Industry Perspective on Drug-Eluting Technologies Guidance

TCT 41: A prospective multicentre randomized all-comers trial to assess the safety and effectiveness of the ultra-thin-strut sirolimus-eluting coronary stent Supraflex: 2-year results of the TALENT trial

FDA Perspective and Revised Guidance

New Data Regarding Drug-Eluting Technologies

An Unforeseen Setback: Summary Level Meta-Analysis Brings Practice Back to the 1990s.

Case Example: Contemporary DES Thrombosis

Drug-Eluting Stent Thrombosis and Restenosis: Mechanisms, Frequency, and Treatment

Case Example: Complex DES With Long-Term Outcomes

Drug-Eluting Stent Platforms and Outcomes 2019

Drug-Coated Balloons: State of the Art in the Face of Controversy

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

My Takeaways From TCT 2018: Sunglasses, Shadows, and the COAPT Eclipse

Off Script: Phantom Hearts and the Elusive Nature of Angina

Human vs Machine: Computer Algorithm Matches Experts for PCI Appropriateness and Planning

Twitter, Bias, and Trial Tweaks: ISCHEMIA Invites Debate on Study Designs and Endpoint Combos

‘Enabling Strategies’ Improve Success of Chronic Total Occlusion PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content